scholarly article | Q13442814 |
P50 | author | Edmund K Waller | Q59682183 |
Joseph H Antin | Q89778009 | ||
Margaret L MacMillan | Q93064323 | ||
Stephan A Grupp | Q104495066 | ||
David L. Porter | Q110797660 | ||
Laura J. Johnston | Q116194191 | ||
P2093 | author name string | Marcelo Pasquini | |
Philip McCarthy | |||
Corey Cutler | |||
Juan Wu | |||
Jack W Hsu | |||
Zhen-Huan Hu | |||
Brent Logan | |||
Mary M Horowitz | |||
Ryotaro Nakamura | |||
Sung Choi | |||
William J Hogan | |||
Shelly L Carter | |||
P2860 | cites work | Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials | Q30997153 |
Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation | Q33366979 | ||
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens | Q33387336 | ||
Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis | Q33403897 | ||
Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group | Q33862023 | ||
Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation | Q34249446 | ||
Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. | Q34451427 | ||
Reduced mortality after allogeneic hematopoietic-cell transplantation | Q34472861 | ||
Cytokine dysregulation and acute graft-versus-host disease | Q35607602 | ||
Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation | Q35750957 | ||
Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation | Q35845541 | ||
Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia | Q35953348 | ||
Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis | Q36206849 | ||
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation | Q36662042 | ||
Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation | Q37001941 | ||
Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). | Q37169115 | ||
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation | Q37247581 | ||
The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. | Q37670062 | ||
Mycophenolate mofetil vs. methotrexate for the prevention of graft-versus-host-disease--systematic review and meta-analysis | Q38178000 | ||
1994 Consensus Conference on Acute GVHD Grading | Q39513397 | ||
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. | Q42552189 | ||
Prediction of veno-occlusive disease using biomarkers of endothelial injury | Q42737854 | ||
A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis | Q43183770 | ||
Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation | Q43790464 | ||
Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia | Q44237334 | ||
Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens | Q46450537 | ||
Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. | Q54684597 | ||
Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease | Q68882743 | ||
Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial | Q73933735 | ||
Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: oral mucositis patient provider advisory board | Q74664011 | ||
Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation | Q78410438 | ||
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P1104 | number of pages | 6 | |
P304 | page(s) | 1372-1377 | |
P577 | publication date | 2014-06-30 | |
P1433 | published in | Blood | Q885070 |
P1476 | title | Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. | |
P478 | volume | 124 |